Antisense compounds, compositions and methods are provided for modulating the expression of Y-box binding protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Y-box binding protein 1. Methods of using these compounds for modulation of Y-box binding protein 1 expression and for treatment of diseases associated with expression of Y-box binding protein 1 are provided.
Claims What is claimed is: 1. An antisense compound 8 to 30 nucleobases in length targeted to the 5'UTR a nucleic acid molecule encoding human Y-box binding protein 1, wherein said antisense compound specifically hybridizes with and inhibits the expression of human Y-box binding protein 1. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. An antisense compound up to 30 nucleobases in length targeted to a nucleic acid molecule encoding human Y-box binding protein 1 comprising at least an 8 nucleobase portion of SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 29, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 49, 50, 51, 52, 54, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 71, 73, 74, 76, 77, 79, 80, 83, 86 or 89 and which inhibits expression of human Y-box binding protein 1. 4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of Y-box binding protein 1 in human cells or tissues in vitro comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of Y-box binding protein 1 is inhibited. 15. The antisense compound of claim 3 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23 further comprising a colloidal dispersion system. 25. The composition of claim 23 wherein the antisense compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of Y-box binding protein 1 in human cells or tissues in vitro comprising contacting said cells or tissues in vitro with the antisense compound of claim 3 so that the expression of Y-box protein 1 is inhibited. 